Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy

Mayo Clinic Proceedings

Volumn 83, Issue 6, 2008, Pages 630-638

  Olivotto, Iacopo ^a,g   Girolami, Francesca ^a   Ackerman, Michael J ^d,e   Nistri, Stefano ^b   Bos, J Martijn ^d   Zachara, Elisabetta ^c   Ommen, Steve R ^d   Theis, Jeanne L ^d   Vaubel, Rachael A ^f   Re, Federica ^c   Armentano, Corinna ^a   Poggesi, Corrado ^a   Torricelli, Francesca ^a   Cecchi, Franco ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CMSR Altavilla Vicentina   (Italy)

^c SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^d MAYO CLINIC   (United States)

^e MAYO GRADUATE SCHOOL   (United States)

^f MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^g CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ACTIN; ALPHA TROPOMYOSIN; MUSCLE PROTEIN; MYOSIN BINDING PROTEIN C; MYOSIN HEAVY CHAIN BETA; MYOSIN LIGHT CHAIN; MYOSIN LIGHT CHAIN 2; MYOSIN LIGHT CHAIN 3; SARCOMERE PROTEIN; TROPONIN I; TROPONIN T;

ADULT; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; FRAMESHIFT MUTATION; GENE MUTATION; GENETIC SUSCEPTIBILITY; HAZARD RATIO; HEART DEATH; HEART EJECTION FRACTION; HEART LEFT VENTRICLE CONTRACTION; HEART VENTRICLE FILLING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MUTATIONAL ANALYSIS; NONSENSE MUTATION; OUTCOME ASSESSMENT; PHENOTYPE; PROBABILITY; RISK ASSESSMENT; RNA SPLICING; SARCOMERE; STROKE; SYSTOLIC DYSFUNCTION;

EID: 44949259297     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/83.6.630     Document Type: Article

References (39)

1. Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol. 2003;42:1687-1713.
2. Ho CY, Seidman CE. A contemporary approach to hypertrophic cardiomyopathy. Circulation. 2006;113(2):e858-e862.
3. Elliott P, McKenna WJ. Hypertrophic cardiomyopathy. Lancet. 2004; 363(9424):1881-1891.
4. Richard P, Charron P, Carrier L, et al. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation. 2003 May 6;107(17):2227-2232. Epub 2003 Apr 21.
5. Erdmann J, Daehmlow S, Wischke S, et al. Mutational spectrum in a large cohort of unrelated consecutive patients with hypertrophic cardiomyopathy. Clin Genet. 2000;64:339-349.
6. Van Driest SL, Ellsworth EG, Ommen SR, Tajik AJ, Gersh BJ, Ackerman MJ. Prevalence and spectrum of thin filament mutations in an outpatient referral population with hypertrophic cardiomyopathy. Circulation. 2003 Jul 29;108(4):445-451. Epub 2003 Jul 14.
7. Van Driest SL, Jaeger M, Ommen SR, et al. Comprehensive analysis of the beta-myosin heavy chain gene in 389 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2004;44(3):602-610.
8. Taylor MR, Carniel E, Mestroni L. Familial hypertrophic cardiomyopathy: clinical features, molecular genetics and molecular genetic testing. Expert Rev Mol Diagn. 2004;4(1):99-113.
9. Thierfelder L, Watkins H, MacRae C, et al. Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell. 1994;77(5):701-712.
10. Watkins H, McKenna WJ, Thierfelder L, et al. Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med. 1995;332(16):1058-1064.
11. Niimura H, Bachinski LL, Sangwatanaroj S, et al. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N Engl J Med. 1998;338(18):1248-1257.
12. Moolman JC, Corfield VA, Posen B, et al. Sudden death due to troponin T mutations. J Am Coll Cardiol. 1997;29(3):549-555.
13. Torricelli F, Girolami F, Olivotto I, et al. Prevalence and clinical profile of troponin T mutations among patients with hypertrophic cardiomyopathy in Tuscany. Am J Cardiol. 2003;92(11):1358-1362.
14. Ackerman MJ, Van Driest SL, Ommen SR, et al. Prevalence and age-dependence of malignant mutations in the beta-myosin heavy chain and troponin T genes in hypertrophic cardiomyopathy: a comprehensive outpatient perspective. J Am Coll Cardiol. 2002;39(12):2042-2048.
15. Binder J, Ommen SR, Gersh BJ, et al. Echocardiography-guided genetic testing in hypertrophic cardiomyopathy: septal morphological features predict the presence of myofilament mutations. Mayo Clin Proc. 2006;81:459-467.
16. Xiao W, Oefner PJ. Denaturing high-performance liquid chromatography: a review. Hum Mutat. 2001;17(6):439-474.
17. Yu B, Sawyer NA, Caramins M, et al. Denaturing high performance liquid chromatography: high throughput mutation screening in familial hypertrophic cardiomyopathy and SNP genotyping in motor neurone disease. J Clin Pathol. 2005;58(5):479-485.
18. Cotton RG, Horaitis O. Quality control in the discovery, reporting, and recording of genomic variation. Hum Mutat. 2000;15(1):16-21.
19. Cecchi F, Olivotto I, Montereggi A, Santoro G, Dolara A, Maron BJ. Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population. J Am Coll Cardiol. 1995;26(6):1529-1536.
20. Yamamoto K, Nishimura RA, Chaliki HP, Appleton CP, Holmes DR Jr, Redfield MM. Determination of left ventricular filling pressure by Doppler echocardiography in patients with coronary artery disease: critical role of left ventricular systolic function. J Am Coll Cardiol. 1997;30(7):1819-1826.
21. Pinamonti B, Di Lenarda A, Sinagra G, Camerini F, Heart Muscle Disease Study Group. Restrictive left ventricular filling pattern in dilated cardiomyopathy assessed by Doppler echocardiography: clinical, echocardiographic and hemodynamic correlations and prognostic implications. J Am Coll Cardiol. 1993;22(3):808-815.
22. Kubo T, Kitaoka H, Okawa M, et al. Lifelong left ventricular remodeling of hypertrophic cardiomyopathy caused by a founder frameshift deletion mutation in the cardiac myosin-binding protein C gene among Japanese. J Am Coll Cardiol. 2005 Nov 1;46(9):1737-1743. Epub 2005 Oct 10.
23. Ashrafian H, Watkins H. Reviews of translational medicine and genomics in cardiovascular disease: new disease taxonomy and therapeutic implications. J Am Coll Cardiol. 2007 Mar 27;49(12):1251-1264. Epub 2007 Mar 9.
24. Harris KM, Spirito P, Maron MS, et al. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation. 2006 Jul 18;114(3):216-225. Epub 2006 Jul 10.
25. Flashman E, Redwood C, Moolman-Smook J, Watkins H. Cardiac myosin binding protein C: its role in physiology and disease. Circ Res. 2004;94 (10):1279-1289.
26. Maron MS, Olivotto I, Betocchi S, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med. 2003;348(4):295-303.
27. Arad M, Maron BJ, Gorham JM, et al. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med. 2005;352(4):362-372.
28. Blair E, Redwood C, Ashrafian H, et al. Mutation in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis. Hum Mol Genet. 2001;10(11):1215-1220.
29. Marian AJ, Roberts R. The molecular genetic basis for hypertrophic cardiomyopathy. J Mol Cell Cardiol. 2001;33(4):655-670.
30. Keller DI, Coirault C, Rau T, et al. Human homozygous R403W mutant cardiac myosin presents disproportionate enhancement of mechanical and enzymatic properties. J Mol Cell Cardiol. 2004;36(3):355-362.
31. Belus A, Piroddi N, Cecchi F, et al. Kinetics of contraction and relaxation in single myofibrils from familial hypertrophic cardiomyopathy patients [abstract]. Biophys J. 2005;88:A19.
32. Crilley JG, Boehm EA, Blair E, et al. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J Am Coll Cardiol. 2003;41(10): 1776-1782.
33. Spindler M, Saupe KW, Christe ME, et al. Diastolic dysfunction and altered energetics in the alphaMHC403/+ mouse model of familial hypertrophic cardiomyopathy. J Clin Invest. 1998;101(8):1775-1783.
34. Javadpour MM, Tardiff JC, Pinz I, Ingwall JS. Decreased energetics in murine hearts bearing the R92Q mutation in cardiac troponin T. J Clin Invest. 2003;112(5):768-775.
35. Van Driest SL, Gakh O, Ommen SR, Isaya G, Ackerman MJ. Molecular and functional characterization of a human frataxin mutation found in hypertrophic cardiomyopathy. Mol Genet Metab. 2005;85(4):280-285.
36. Ho CY, Lever HM, DeSanctis R, Farver CF, Seidman JG, Seidman CE. Homozygous mutation in cardiac troponin T: implications for hypertrophic cardiomyopathy. Circulation. 2000;102(16):1950-1955.
37. Van Driest SL, Vasile VC, Ommen SR, et al. Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2004;44(9):1903-1910.
38. Alcalai R, Seidman JG, Seidman CE. Genetic basis of hypertrophic cardiomyopathy: from bench to the clinics. J Cardiovasc Electrophysiol. 2008 Jan;19:104-110. Epub 2007 Oct 4.
39. Vasile VC, Ommen SR, Edwards WD, Ackerman MJ. A missense mutation in a ubiquitously expressed protein, vinculin, confers susceptibility to hypertrophic cardiomyopathy. Biochem Biophys Res Commun. 2006;345(3): 998-1003.